Incyte Corporation
$97.69
▲
1.53%
2026-04-22 10:12:13
www.incyte.com
NMS: INCY
Explore Incyte Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$19.46 B
Current Price
$97.69
52W High / Low
$112.29 / $56.13
Stock P/E
15.26
Book Value
$26.04
Dividend Yield
—
ROCE
24.67%
ROE
29.87%
Face Value
—
EPS
$6.41
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2,844
Beta
0.86
Debt / Equity
1.06
Current Ratio
3.32
Quick Ratio
3.25
Forward P/E
11.11
Price / Sales
3.72
Enterprise Value
$15.59 B
EV / EBITDA
10.83
EV / Revenue
3.03
Rating
Buy
Target Price
$107.27
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | LeonaBio, Inc. | $9.38 | — | $83.23 M | — | -76.55% | -2.91% | $14.21 / $2.2 | $5.2 |
| 2. | Sensei Biotherapeutics, Inc. | $31.39 | — | $42.07 M | — | -119.5% | -74.01% | $36.76 / $5.25 | $18.24 |
| 3. | Entera Bio Ltd. | $1.34 | — | $62.47 M | — | -83.6% | -1.08% | $3.22 / $0.91 | $0.28 |
| 4. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 5. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 6. | Skye Bioscience, Inc. | $0.78 | — | $26.15 M | — | -289.25% | -1.27% | $5.75 / $0.57 | $0.6 |
| 7. | Unicycive Therapeutics, Inc. | $7.43 | — | $177.17 M | — | -97.75% | -1.41% | $11 / $3.71 | $1.36 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 1.51 B | 1.37 B | 1.22 B | 1.05 B | 1.18 B |
| Operating Profit | 383.96 M | 431.3 M | 310.81 M | 216.72 M | 297.36 M |
| Net Profit | 299.28 M | 424.17 M | 405 M | 158.2 M | 201.21 M |
| EPS in Rs | 1.5 | 2.13 | 2.04 | 0.79 | 1.01 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 5.14 B | 4.24 B | 3.7 B | 3.39 B |
| Operating Profit | 1.34 B | 101.29 M | 655.36 M | 591.63 M |
| Net Profit | 1.29 B | 32.62 M | 597.6 M | 340.66 M |
| EPS in Rs | 6.47 | 0.16 | 3 | 1.71 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.96 B | 5.44 B | 6.78 B | 5.84 B |
| Total Liabilities | 1.79 B | 2 B | 1.59 B | 1.47 B |
| Equity | 5.17 B | 3.45 B | 5.19 B | 4.37 B |
| Current Assets | 5.02 B | 3.24 B | 4.65 B | 4.09 B |
| Current Liabilities | 1.52 B | 1.64 B | 1.24 B | 1.16 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 1.41 B | 335.34 M | 496.49 M | 969.94 M |
| Investing CF | -102.61 M | 157.52 M | -207.68 M | -78.54 M |
| Financing CF | 101.04 M | -2.02 B | -20.03 M | -0.79 M |
| Free CF | 1.33 B | 235.17 M | 449 M | 892.11 M |
| Capex | -83.87 M | -100.16 M | -47.49 M | -77.83 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 14.76% | 8.87% | — | — |
| Earnings Growth % | -94.54% | 75.42% | — | — |
| Profit Margin % | 0.77% | 16.17% | 10.04% | — |
| Operating Margin % | 2.39% | 17.73% | 17.43% | — |
| Gross Margin % | 92.64% | 93.1% | 93.9% | — |
| EBITDA Margin % | 9.62% | 24.88% | 17.66% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.